Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 13

CHRM3 rs2165870 Polymorphism Correlates with Postoperative Nausea and Vomiting Incidence and the Efficacy of Ondansetron in a Chinese Han Population

Authors Wang J, Li Y, Zheng C, Sun Y, Yang J

Received 18 March 2020

Accepted for publication 20 July 2020

Published 13 August 2020 Volume 2020:13 Pages 319—326


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Martin Bluth

Jiayu Wang,1,2 Yang Li,3 Cuijuan Zheng,2 Yan Sun,1 Jianping Yang1

1Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 2Department of Anesthesiology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian 223300, Jiangsu, People’s Republic of China; 3Jiangsu College of Nursing, Huaian 223300, Jiangsu, People’s Republic of China

Correspondence: Jianping Yang Email

Background: Previous GWAS studies have shown that there is a relationship between M3 muscarinic acetylcholine receptor (CHRM3) rs2165870 polymorphism and postoperative nausea and vomiting (PONV) incidence. However, no Chinese studies have addressed this issue.
Methods: To explore the relationship between CHRM3 rs2165870 polymorphism and PONV incidence in a Chinese Han population, we enrolled 512 patients receiving elective surgery in this study. CHRM3 rs2165870 polymorphism was genotyped using PCR-RFLP method.
Results: We found that AA genotype or A allele of CHRM3 rs2165870 polymorphism elevated the risk of PONV (AA versus GG; OR, 2.88; 95% CI, 1.51– 5.47; P = 0.001; A versus G; OR, 1.39; 95% CI, 1.07– 1.81; P = 0.013). In addition, CHRM3 rs2165870 polymorphism was related to the risk of PONV among the males, smokers, and those individuals with Apfel Score 3– 4 or ASA classification 2– 3. Last, we assessed the effects of CHRM3 rs2165870 polymorphism on the treatment efficacy of ondansetron for PONV. Data uncovered that 103 of 209 patients (49.3%) showed response to ondansetron treatment for PONV. The PONV incidence was significantly higher in AA genotype carriers compared with GG genotype carriers during the first 2 h after surgery, but not from 2 to 24 h after surgery.
Conclusion: To sum up, this study reveals that CHRM3 rs2165870 polymorphism is related to the incidence of PONV and treatment effects of ondansetron for preventing PONV in this Chinese Han population.

Keywords: postoperative nausea and vomiting, CHRM3, single nucleotide polymorphism, ondansetron

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]